- Home
- NPCE vs ARDC Comparison
NPCE vs ARDC Comparison
Compare NPCE & ARDC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NPCE
- ARDC
- Stock Information
- Founded
- NPCE 1997
- ARDC 2012
- Country
- NPCE United States
- ARDC United States
- Employees
- NPCE N/A
- ARDC N/A
- Industry
- NPCE Medical Specialities
- ARDC Investment Managers
- Sector
- NPCE Health Care
- ARDC Finance
- Exchange
- NPCE Nasdaq
- ARDC Nasdaq
- Market Cap
- NPCE 342.7M
- ARDC 334.0M
- IPO Year
- NPCE 2021
- ARDC N/A
- Fundamental
- Price
- NPCE $10.82
- ARDC $13.58
- Analyst Decision
- NPCE Strong Buy
- ARDC
- Analyst Count
- NPCE 6
- ARDC 0
- Target Price
- NPCE $16.67
- ARDC N/A
- AVG Volume (30 Days)
- NPCE 149.8K
- ARDC 115.8K
- Earning Date
- NPCE 11-11-2025
- ARDC 01-01-0001
- Dividend Yield
- NPCE N/A
- ARDC 9.84%
- EPS Growth
- NPCE N/A
- ARDC N/A
- EPS
- NPCE N/A
- ARDC N/A
- Revenue
- NPCE $88,570,000.00
- ARDC N/A
- Revenue This Year
- NPCE $22.13
- ARDC N/A
- Revenue Next Year
- NPCE $6.07
- ARDC N/A
- P/E Ratio
- NPCE N/A
- ARDC N/A
- Revenue Growth
- NPCE 23.32
- ARDC N/A
- 52 Week Low
- NPCE $5.45
- ARDC $11.56
- 52 Week High
- NPCE $18.98
- ARDC $14.30
- Technical
- Relative Strength Index (RSI)
- NPCE 57.95
- ARDC 29.13
- Support Level
- NPCE $10.25
- ARDC $13.36
- Resistance Level
- NPCE $11.25
- ARDC $13.79
- Average True Range (ATR)
- NPCE 0.50
- ARDC 0.19
- MACD
- NPCE -0.02
- ARDC -0.04
- Stochastic Oscillator
- NPCE 65.44
- ARDC 29.42
About NPCE Neuropace Inc.
NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all of its revenue from the sales of RNS Systems to hospital facilities (typically Level 4 CECs) that implant RNS Systems.
About ARDC Ares Dynamic Credit Allocation Fund Inc.
Ares Dynamic Credit Allocation Fund Inc is a closed-ended, diversified management investment company. The fund's investment objective is to provide an attractive level of total return, through current income and, secondarily, through capital appreciation. The Fund invests in a broad, dynamically managed portfolio of senior secured loans (Senior Loans) made to companies whose debt is rated below investment grade; corporate bonds (Corporate Bonds) that are high yield issues rated below investment grade; other fixed-income instruments of a similar nature that may be represented by derivatives; and securities of collateralized loan obligations (CLOs).